speb/financial-data huggingface dataset:
TORNTPHARM.NS income_statement (quarterly, 2025-03-31) — Total Unusual Items Excluding Goodwill: -240000000.00
TORNTPHARM.NS balance_sheet (annual, 2025-03-31) — Work In Process: 1671900000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Work In Process: 1671900000.00
TORNTPHARM.NS balance_sheet (annual, 2025-03-31) — Working Capital: 9053800000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-03-31) — Working Capital: 9053800000.00
TORNTPHARM.NS income_statement (quarterly, 2025-06-30) — +Operating Expense: 15230000000.00
TORNTPHARM.NS income_statement (quarterly, 2025-06-30) — +Total Revenue: 31280000000.00
TORNTPHARM.NS income_statement (quarterly, 2025-06-30) — Basic Average Shares: 338480544.00
TORNTPHARM.NS income_statement (quarterly, 2025-06-30) — Basic EPS: 16.19
TORNTPHARM.NS income_statement (quarterly, 2025-06-30) — Cost Of Revenue: 7740000000.00
TORNTPHARM.NS income_statement (quarterly, 2025-06-30) — Depreciation And Amortization In Income Statement: 2010000000.00
TORNTPHARM.NS income_statement (quarterly, 2025-06-30) — Depreciation Income Statement: 2010000000.00
TORNTPHARM.NS income_statement (quarterly, 2025-06-30) — Diluted Average Shares: 338480544.00
TORNTPHARM.NS income_statement (quarterly, 2025-06-30) — Diluted EPS: 16.19
TORNTPHARM.NS income_statement (quarterly, 2025-06-30) — Diluted NI Availto Com Stockholders: 5480000000.00
TORNTPHARM.NS income_statement (quarterly, 2025-06-30) — EBIT: 7940000000.00
TORNTPHARM.NS income_statement (quarterly, 2025-06-30) — EBITDA: 9950000000.00
TORNTPHARM.NS income_statement (quarterly, 2025-06-30) — Gross Profit: 23540000000.00
TORNTPHARM.NS income_statement (quarterly, 2025-06-30) — Interest Expense: 560000000.00
TORNTPHARM.NS income_statement (quarterly, 2025-06-30) — Interest Expense Non Operating: 560000000.00
TORNTPHARM.NS income_statement (quarterly, 2025-06-30) — Minority Interests: 0.00
TORNTPHARM.NS income_statement (quarterly, 2025-06-30) — Net Income: 5480000000.00
TORNTPHARM.NS income_statement (quarterly, 2025-06-30) — Net Income Common Stockholders: 5480000000.00
TORNTPHARM.NS income_statement (quarterly, 2025-06-30) — Net Income Continuous Operations: 5480000000.00
TORNTPHARM.NS income_statement (quarterly, 2025-06-30) — Net Income From Continuing And Discontinued Operation: 5480000000.00
TORNTPHARM.NS income_statement (quarterly, 2025-06-30) — Net Income From Continuing Operation Net Minority Interest: 5480000000.00
TORNTPHARM.NS income_statement (quarterly, 2025-06-30) — Net Income Including Noncontrolling Interests: 5480000000.00
TORNTPHARM.NS income_statement (quarterly, 2025-06-30) — Net Interest Income: -560000000.00
TORNTPHARM.NS income_statement (quarterly, 2025-06-30) — Net Non Operating Interest Income Expense: -560000000.00
TORNTPHARM.NS income_statement (quarterly, 2025-06-30) — Normalized EBITDA: 9950000000.00
TORNTPHARM.NS income_statement (quarterly, 2025-06-30) — Normalized Income: 5480000000.00
TORNTPHARM.NS income_statement (quarterly, 2025-06-30) — Operating Income: 8310000000.00
TORNTPHARM.NS income_statement (quarterly, 2025-06-30) — Operating Revenue: 31280000000.00
TORNTPHARM.NS income_statement (quarterly, 2025-06-30) — Other Non Operating Income Expenses: -370000000.00
TORNTPHARM.NS income_statement (quarterly, 2025-06-30) — Other Operating Expenses: 7670000000.00
TORNTPHARM.NS income_statement (quarterly, 2025-06-30) — Otherunder Preferred Stock Dividend: 0.00
TORNTPHARM.NS income_statement (quarterly, 2025-06-30) — Pretax Income: 7380000000.00
TORNTPHARM.NS income_statement (quarterly, 2025-06-30) — Reconciled Cost Of Revenue: 7740000000.00
TORNTPHARM.NS income_statement (quarterly, 2025-06-30) — Reconciled Depreciation: 2010000000.00
TORNTPHARM.NS income_statement (quarterly, 2025-06-30) — Special Income Charges: 0.00
TORNTPHARM.NS income_statement (quarterly, 2025-06-30) — Tax Effect Of Unusual Items: 0.00
TORNTPHARM.NS income_statement (quarterly, 2025-06-30) — Tax Provision: 1900000000.00
TORNTPHARM.NS income_statement (quarterly, 2025-06-30) — Tax Rate For Calcs: 0.26
TORNTPHARM.NS income_statement (quarterly, 2025-06-30) — Total Expenses: 22970000000.00
TORNTPHARM.NS income_statement (quarterly, 2025-06-30) — Total Unusual Items: 0.00
TORNTPHARM.NS income_statement (quarterly, 2025-06-30) — Total Unusual Items Excluding Goodwill: 0.00
TORNTPHARM.NS income_statement (quarterly, 2025-09-30) — +Operating Expense: 15670000000.00
TORNTPHARM.NS income_statement (quarterly, 2025-09-30) — +Total Revenue: 32460000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-09-30) — Accounts Payable: 16750000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-09-30) — Accounts Receivable: 21850000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-09-30) — Available For Sale Securities: 710000000.00
TORNTPHARM.NS income_statement (quarterly, 2025-09-30) — Basic Average Shares: 338681948.00
TORNTPHARM.NS income_statement (quarterly, 2025-09-30) — Basic EPS: 17.45
TORNTPHARM.NS balance_sheet (quarterly, 2025-09-30) — Capital Lease Obligations: 2320000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-09-30) — Capital Stock: 1690000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-09-30) — Cash And Cash Equivalents: 6210000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-09-30) — Cash Cash Equivalents And Short Term Investments: 10330000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-09-30) — Common Stock: 1690000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-09-30) — Common Stock Equity: 84490000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-09-30) — Construction In Progress: 4880000000.00
TORNTPHARM.NS income_statement (quarterly, 2025-09-30) — Cost Of Revenue: 8000000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-09-30) — Current Assets: 61710000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-09-30) — Current Capital Lease Obligation: 340000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-09-30) — Current Debt: 15450000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-09-30) — Current Debt And Capital Lease Obligation: 15790000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-09-30) — Current Liabilities: 44350000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-09-30) — Current Provisions: 4600000000.00
TORNTPHARM.NS income_statement (quarterly, 2025-09-30) — Depreciation And Amortization In Income Statement: 2040000000.00
TORNTPHARM.NS income_statement (quarterly, 2025-09-30) — Depreciation Income Statement: 2040000000.00
TORNTPHARM.NS income_statement (quarterly, 2025-09-30) — Diluted Average Shares: 338681948.00
TORNTPHARM.NS income_statement (quarterly, 2025-09-30) — Diluted EPS: 17.45
TORNTPHARM.NS income_statement (quarterly, 2025-09-30) — Diluted NI Availto Com Stockholders: 5910000000.00
TORNTPHARM.NS income_statement (quarterly, 2025-09-30) — EBIT: 8390000000.00
TORNTPHARM.NS income_statement (quarterly, 2025-09-30) — EBITDA: 10430000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-09-30) — Goodwill: 3400000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-09-30) — Goodwill And Other Intangible Assets: 43830000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-09-30) — Gross PPE: 39460000000.00
TORNTPHARM.NS income_statement (quarterly, 2025-09-30) — Gross Profit: 24460000000.00
TORNTPHARM.NS income_statement (quarterly, 2025-09-30) — Interest Expense: 480000000.00
TORNTPHARM.NS income_statement (quarterly, 2025-09-30) — Interest Expense Non Operating: 480000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-09-30) — Inventory: 24670000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-09-30) — Invested Capital: 110390000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-09-30) — Investmentin Financial Assets: 710000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-09-30) — Long Term Capital Lease Obligation: 1980000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-09-30) — Long Term Debt: 10450000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-09-30) — Long Term Debt And Capital Lease Obligation: 12430000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-09-30) — Long Term Provisions: 5410000000.00
TORNTPHARM.NS income_statement (quarterly, 2025-09-30) — Minority Interests: 0.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-09-30) — Net Debt: 19690000000.00
TORNTPHARM.NS income_statement (quarterly, 2025-09-30) — Net Income: 5910000000.00
TORNTPHARM.NS income_statement (quarterly, 2025-09-30) — Net Income Common Stockholders: 5910000000.00
TORNTPHARM.NS income_statement (quarterly, 2025-09-30) — Net Income Continuous Operations: 5910000000.00
TORNTPHARM.NS income_statement (quarterly, 2025-09-30) — Net Income From Continuing And Discontinued Operation: 5910000000.00
TORNTPHARM.NS income_statement (quarterly, 2025-09-30) — Net Income From Continuing Operation Net Minority Interest: 5910000000.00
TORNTPHARM.NS income_statement (quarterly, 2025-09-30) — Net Income Including Noncontrolling Interests: 5910000000.00
TORNTPHARM.NS income_statement (quarterly, 2025-09-30) — Net Interest Income: -480000000.00
TORNTPHARM.NS income_statement (quarterly, 2025-09-30) — Net Non Operating Interest Income Expense: -480000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-09-30) — Net PPE: 39460000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-09-30) — Net Tangible Assets: 40660000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-09-30) — Non Current Deferred Taxes Assets: 6530000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-09-30) — Non Current Deferred Taxes Liabilities: 7850000000.00
TORNTPHARM.NS income_statement (quarterly, 2025-09-30) — Normalized EBITDA: 10560000000.00
TORNTPHARM.NS income_statement (quarterly, 2025-09-30) — Normalized Income: 6007130214.92
TORNTPHARM.NS income_statement (quarterly, 2025-09-30) — Operating Income: 8790000000.00
TORNTPHARM.NS income_statement (quarterly, 2025-09-30) — Operating Revenue: 32460000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-09-30) — Ordinary Shares Number: 338445440.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-09-30) — Other Current Assets: 4810000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-09-30) — Other Current Liabilities: 1260000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-09-30) — Other Equity Interest: 82800000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-09-30) — Other Intangible Assets: 40430000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-09-30) — Other Non Current Assets: 260000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-09-30) — Other Non Current Liabilities: 50000000.00
TORNTPHARM.NS income_statement (quarterly, 2025-09-30) — Other Non Operating Income Expenses: -270000000.00
TORNTPHARM.NS income_statement (quarterly, 2025-09-30) — Other Operating Expenses: 7920000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-09-30) — Other Properties: 34580000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-09-30) — Other Receivables: 50000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-09-30) — Other Short Term Investments: 4120000000.00
TORNTPHARM.NS income_statement (quarterly, 2025-09-30) — Otherunder Preferred Stock Dividend: 0.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-09-30) — Payables: 18050000000.00
TORNTPHARM.NS income_statement (quarterly, 2025-09-30) — Pretax Income: 7910000000.00
TORNTPHARM.NS income_statement (quarterly, 2025-09-30) — Reconciled Cost Of Revenue: 8000000000.00
TORNTPHARM.NS income_statement (quarterly, 2025-09-30) — Reconciled Depreciation: 2040000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-09-30) — Share Issued: 338445440.00
TORNTPHARM.NS income_statement (quarterly, 2025-09-30) — Special Income Charges: -130000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-09-30) — Stockholders Equity: 84490000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-09-30) — Tangible Book Value: 40660000000.00
TORNTPHARM.NS income_statement (quarterly, 2025-09-30) — Tax Effect Of Unusual Items: -32869785.08
TORNTPHARM.NS income_statement (quarterly, 2025-09-30) — Tax Provision: 2000000000.00
TORNTPHARM.NS income_statement (quarterly, 2025-09-30) — Tax Rate For Calcs: 0.25
TORNTPHARM.NS balance_sheet (quarterly, 2025-09-30) — Total Assets: 155150000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-09-30) — Total Capitalization: 94940000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-09-30) — Total Debt: 28220000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-09-30) — Total Equity Gross Minority Interest: 84490000000.00
TORNTPHARM.NS income_statement (quarterly, 2025-09-30) — Total Expenses: 23670000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-09-30) — Total Liabilities Net Minority Interest: 70660000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-09-30) — Total Non Current Assets: 93440000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-09-30) — Total Non Current Liabilities Net Minority Interest: 26310000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-09-30) — Total Tax Payable: 1300000000.00
TORNTPHARM.NS income_statement (quarterly, 2025-09-30) — Total Unusual Items: -130000000.00
TORNTPHARM.NS income_statement (quarterly, 2025-09-30) — Total Unusual Items Excluding Goodwill: -130000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2025-09-30) — Working Capital: 17360000000.00
TORNTPHARM.NS income_statement (quarterly, 2025-12-31) — +Operating Expense: 15700000000.00
TORNTPHARM.NS income_statement (quarterly, 2025-12-31) — +Total Revenue: 32510000000.00
TORNTPHARM.NS income_statement (quarterly, 2025-12-31) — Basic Average Shares: 338305807.00
TORNTPHARM.NS income_statement (quarterly, 2025-12-31) — Basic EPS: 18.77
TORNTPHARM.NS income_statement (quarterly, 2025-12-31) — Cost Of Revenue: 7990000000.00
TORNTPHARM.NS income_statement (quarterly, 2025-12-31) — Depreciation And Amortization In Income Statement: 2060000000.00
TORNTPHARM.NS income_statement (quarterly, 2025-12-31) — Depreciation Income Statement: 2060000000.00
TORNTPHARM.NS income_statement (quarterly, 2025-12-31) — Diluted Average Shares: 338305807.00
TORNTPHARM.NS income_statement (quarterly, 2025-12-31) — Diluted EPS: 18.77
TORNTPHARM.NS income_statement (quarterly, 2025-12-31) — Diluted NI Availto Com Stockholders: 6350000000.00
TORNTPHARM.NS income_statement (quarterly, 2025-12-31) — EBIT: 8590000000.00
TORNTPHARM.NS income_statement (quarterly, 2025-12-31) — EBITDA: 10650000000.00
TORNTPHARM.NS income_statement (quarterly, 2025-12-31) — Gross Profit: 24520000000.00
TORNTPHARM.NS income_statement (quarterly, 2025-12-31) — Interest Expense: 450000000.00
TORNTPHARM.NS income_statement (quarterly, 2025-12-31) — Interest Expense Non Operating: 450000000.00
TORNTPHARM.NS income_statement (quarterly, 2025-12-31) — Minority Interests: 0.00
TORNTPHARM.NS income_statement (quarterly, 2025-12-31) — Net Income: 6350000000.00
TORNTPHARM.NS income_statement (quarterly, 2025-12-31) — Net Income Common Stockholders: 6350000000.00
TORNTPHARM.NS income_statement (quarterly, 2025-12-31) — Net Income Continuous Operations: 6350000000.00
TORNTPHARM.NS income_statement (quarterly, 2025-12-31) — Net Income From Continuing And Discontinued Operation: 6350000000.00
TORNTPHARM.NS income_statement (quarterly, 2025-12-31) — Net Income From Continuing Operation Net Minority Interest: 6350000000.00
TORNTPHARM.NS income_statement (quarterly, 2025-12-31) — Net Income Including Noncontrolling Interests: 6350000000.00
TORNTPHARM.NS income_statement (quarterly, 2025-12-31) — Net Interest Income: -450000000.00
TORNTPHARM.NS income_statement (quarterly, 2025-12-31) — Net Non Operating Interest Income Expense: -450000000.00
TORNTPHARM.NS income_statement (quarterly, 2025-12-31) — Normalized EBITDA: 10750000000.00
TORNTPHARM.NS income_statement (quarterly, 2025-12-31) — Normalized Income: 6428009828.01
TORNTPHARM.NS income_statement (quarterly, 2025-12-31) — Operating Income: 8820000000.00
TORNTPHARM.NS income_statement (quarterly, 2025-12-31) — Operating Revenue: 32510000000.00
TORNTPHARM.NS income_statement (quarterly, 2025-12-31) — Other Non Operating Income Expenses: -130000000.00
TORNTPHARM.NS income_statement (quarterly, 2025-12-31) — Other Operating Expenses: 7650000000.00
TORNTPHARM.NS income_statement (quarterly, 2025-12-31) — Other Special Charges: 100000000.00
TORNTPHARM.NS income_statement (quarterly, 2025-12-31) — Otherunder Preferred Stock Dividend: 0.00
TORNTPHARM.NS income_statement (quarterly, 2025-12-31) — Pretax Income: 8140000000.00
TORNTPHARM.NS income_statement (quarterly, 2025-12-31) — Reconciled Cost Of Revenue: 7990000000.00
TORNTPHARM.NS income_statement (quarterly, 2025-12-31) — Reconciled Depreciation: 2060000000.00
TORNTPHARM.NS income_statement (quarterly, 2025-12-31) — Special Income Charges: -100000000.00
TORNTPHARM.NS income_statement (quarterly, 2025-12-31) — Tax Effect Of Unusual Items: -21990171.99
TORNTPHARM.NS income_statement (quarterly, 2025-12-31) — Tax Provision: 1790000000.00
TORNTPHARM.NS income_statement (quarterly, 2025-12-31) — Tax Rate For Calcs: 0.22
TORNTPHARM.NS income_statement (quarterly, 2025-12-31) — Total Expenses: 23690000000.00
TORNTPHARM.NS income_statement (quarterly, 2025-12-31) — Total Unusual Items: -100000000.00
TORNTPHARM.NS income_statement (quarterly, 2025-12-31) — Total Unusual Items Excluding Goodwill: -100000000.00
TORNTPHARM.NS income_statement (annual, 2026-03-31) — +Operating Expense: 67881200000.00
TORNTPHARM.NS income_statement (quarterly, 2026-03-31) — +Operating Expense: 22650000000.00
TORNTPHARM.NS income_statement (annual, 2026-03-31) — +Total Revenue: 137529900000.00
TORNTPHARM.NS income_statement (quarterly, 2026-03-31) — +Total Revenue: 41280000000.00
TORNTPHARM.NS balance_sheet (annual, 2026-03-31) — Accounts Payable: 23576100000.00
TORNTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Accounts Payable: 23576100000.00
TORNTPHARM.NS balance_sheet (annual, 2026-03-31) — Accounts Receivable: 30308600000.00
TORNTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Accounts Receivable: 30308600000.00
TORNTPHARM.NS balance_sheet (annual, 2026-03-31) — Accumulated Depreciation: -25486400000.00
TORNTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Accumulated Depreciation: -25486400000.00
TORNTPHARM.NS balance_sheet (annual, 2026-03-31) — Allowance For Doubtful Accounts Receivable: -586900000.00
TORNTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Allowance For Doubtful Accounts Receivable: -586900000.00
TORNTPHARM.NS income_statement (annual, 2026-03-31) — Amortization: 7994400000.00
TORNTPHARM.NS balance_sheet (annual, 2026-03-31) — Available For Sale Securities: 718000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Available For Sale Securities: 718000000.00
TORNTPHARM.NS income_statement (quarterly, 2026-03-31) — Basic Average Shares: 337966985.00
TORNTPHARM.NS income_statement (quarterly, 2026-03-31) — Basic EPS: 11.51
TORNTPHARM.NS cash_flow (annual, 2026-03-31) — Beginning Cash Position: 5734800000.00
TORNTPHARM.NS balance_sheet (annual, 2026-03-31) — Buildings And Improvements: 23468800000.00
TORNTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Buildings And Improvements: 23468800000.00
TORNTPHARM.NS cash_flow (annual, 2026-03-31) — Capital Expenditure: -6773900000.00
TORNTPHARM.NS balance_sheet (annual, 2026-03-31) — Capital Lease Obligations: 2272600000.00
TORNTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Capital Lease Obligations: 2272600000.00
TORNTPHARM.NS balance_sheet (annual, 2026-03-31) — Capital Stock: 1692300000.00
TORNTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Capital Stock: 1692300000.00
TORNTPHARM.NS balance_sheet (annual, 2026-03-31) — Cash And Cash Equivalents: 11172000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Cash And Cash Equivalents: 11172000000.00
TORNTPHARM.NS balance_sheet (annual, 2026-03-31) — Cash Cash Equivalents And Short Term Investments: 23552100000.00
TORNTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Cash Cash Equivalents And Short Term Investments: 23552100000.00
TORNTPHARM.NS cash_flow (annual, 2026-03-31) — Cash Dividends Paid: -12889400000.00
TORNTPHARM.NS balance_sheet (annual, 2026-03-31) — Cash Equivalents: 6751900000.00
TORNTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Cash Equivalents: 6751900000.00
TORNTPHARM.NS balance_sheet (annual, 2026-03-31) — Cash Financial: 4420100000.00
TORNTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Cash Financial: 4420100000.00
TORNTPHARM.NS cash_flow (annual, 2026-03-31) — Change In Inventory: 343800000.00
TORNTPHARM.NS cash_flow (annual, 2026-03-31) — Change In Other Current Liabilities: -1778700000.00
TORNTPHARM.NS cash_flow (annual, 2026-03-31) — Change In Payable: 1641000000.00
TORNTPHARM.NS cash_flow (annual, 2026-03-31) — Change In Receivables: -3625800000.00
TORNTPHARM.NS cash_flow (annual, 2026-03-31) — Change In Working Capital: -3419700000.00
TORNTPHARM.NS cash_flow (annual, 2026-03-31) — Changes In Cash: 4609000000.00
TORNTPHARM.NS balance_sheet (annual, 2026-03-31) — Common Stock: 1692300000.00
TORNTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Common Stock: 1692300000.00
TORNTPHARM.NS balance_sheet (annual, 2026-03-31) — Common Stock Equity: 83884300000.00
TORNTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Common Stock Equity: 83884300000.00
TORNTPHARM.NS balance_sheet (annual, 2026-03-31) — Construction In Progress: 4855900000.00
TORNTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Construction In Progress: 4855900000.00
TORNTPHARM.NS income_statement (annual, 2026-03-31) — Cost Of Revenue: 35251100000.00
TORNTPHARM.NS income_statement (quarterly, 2026-03-31) — Cost Of Revenue: 10150000000.00
TORNTPHARM.NS balance_sheet (annual, 2026-03-31) — Current Assets: 93918900000.00
TORNTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Current Assets: 93918900000.00
TORNTPHARM.NS balance_sheet (annual, 2026-03-31) — Current Capital Lease Obligation: 371900000.00
TORNTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Current Capital Lease Obligation: 371900000.00
TORNTPHARM.NS balance_sheet (annual, 2026-03-31) — Current Debt: 31470700000.00
TORNTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Current Debt: 31470700000.00
TORNTPHARM.NS balance_sheet (annual, 2026-03-31) — Current Debt And Capital Lease Obligation: 31842600000.00
TORNTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Current Debt And Capital Lease Obligation: 31842600000.00
TORNTPHARM.NS balance_sheet (annual, 2026-03-31) — Current Liabilities: 83433300000.00
TORNTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Current Liabilities: 83433300000.00
TORNTPHARM.NS balance_sheet (annual, 2026-03-31) — Current Provisions: 4987900000.00
TORNTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Current Provisions: 4987900000.00
TORNTPHARM.NS cash_flow (annual, 2026-03-31) — Depreciation: 11188700000.00
TORNTPHARM.NS cash_flow (annual, 2026-03-31) — Depreciation And Amortization: 11188700000.00
TORNTPHARM.NS income_statement (annual, 2026-03-31) — Depreciation And Amortization In Income Statement: 11187000000.00
TORNTPHARM.NS income_statement (quarterly, 2026-03-31) — Depreciation And Amortization In Income Statement: 5080000000.00
TORNTPHARM.NS income_statement (annual, 2026-03-31) — Depreciation Income Statement: 3192600000.00
TORNTPHARM.NS income_statement (quarterly, 2026-03-31) — Depreciation Income Statement: 5080000000.00
TORNTPHARM.NS balance_sheet (annual, 2026-03-31) — Derivative Product Liabilities: 717200000.00
TORNTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Derivative Product Liabilities: 717200000.00
TORNTPHARM.NS income_statement (quarterly, 2026-03-31) — Diluted Average Shares: 337966985.00
TORNTPHARM.NS income_statement (quarterly, 2026-03-31) — Diluted EPS: 11.51
TORNTPHARM.NS income_statement (annual, 2026-03-31) — Diluted NI Availto Com Stockholders: 21633700000.00
TORNTPHARM.NS income_statement (quarterly, 2026-03-31) — Diluted NI Availto Com Stockholders: 3890000000.00
TORNTPHARM.NS balance_sheet (annual, 2026-03-31) — Dividends Payable: 87900000.00
TORNTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Dividends Payable: 87900000.00
TORNTPHARM.NS income_statement (annual, 2026-03-31) — EBIT: 32568800000.00
TORNTPHARM.NS income_statement (quarterly, 2026-03-31) — EBIT: 7650000000.00
TORNTPHARM.NS income_statement (annual, 2026-03-31) — EBITDA: 43757500000.00
TORNTPHARM.NS income_statement (quarterly, 2026-03-31) — EBITDA: 12730000000.00
TORNTPHARM.NS cash_flow (annual, 2026-03-31) — Effect Of Exchange Rate Changes: 828200000.00
TORNTPHARM.NS cash_flow (annual, 2026-03-31) — End Cash Position: 11172000000.00
TORNTPHARM.NS balance_sheet (annual, 2026-03-31) — Financial Assets: 0.00
TORNTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Financial Assets: 0.00
TORNTPHARM.NS balance_sheet (annual, 2026-03-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 276100000.00
TORNTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 276100000.00
TORNTPHARM.NS cash_flow (annual, 2026-03-31) — Financing Cash Flow: 101506000000.00
TORNTPHARM.NS balance_sheet (annual, 2026-03-31) — Finished Goods: 19925600000.00
TORNTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Finished Goods: 19925600000.00
TORNTPHARM.NS cash_flow (annual, 2026-03-31) — Free Cash Flow: 23453200000.00
TORNTPHARM.NS cash_flow (annual, 2026-03-31) — Gain Loss On Investment Securities: -316700000.00
TORNTPHARM.NS cash_flow (annual, 2026-03-31) — Gain Loss On Sale Of PPE: -176600000.00
TORNTPHARM.NS income_statement (annual, 2026-03-31) — General And Administrative Expense: 9011600000.00
TORNTPHARM.NS balance_sheet (annual, 2026-03-31) — Goodwill: 39896200000.00
TORNTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Goodwill: 39896200000.00
TORNTPHARM.NS balance_sheet (annual, 2026-03-31) — Goodwill And Other Intangible Assets: 284531800000.00
TORNTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Goodwill And Other Intangible Assets: 284531800000.00
TORNTPHARM.NS balance_sheet (annual, 2026-03-31) — Gross Accounts Receivable: 30895500000.00
TORNTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Gross Accounts Receivable: 30895500000.00
TORNTPHARM.NS balance_sheet (annual, 2026-03-31) — Gross PPE: 79427600000.00
TORNTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Gross PPE: 79427600000.00
TORNTPHARM.NS income_statement (annual, 2026-03-31) — Gross Profit: 102278800000.00
TORNTPHARM.NS income_statement (quarterly, 2026-03-31) — Gross Profit: 31130000000.00
TORNTPHARM.NS balance_sheet (annual, 2026-03-31) — Hedging Assets Current: 15000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Hedging Assets Current: 15000000.00
TORNTPHARM.NS income_statement (annual, 2026-03-31) — Impairment Of Capital Assets: 1700000.00
TORNTPHARM.NS income_statement (annual, 2026-03-31) — Interest Expense: 3846900000.00
TORNTPHARM.NS income_statement (quarterly, 2026-03-31) — Interest Expense: 2360000000.00
TORNTPHARM.NS income_statement (annual, 2026-03-31) — Interest Expense Non Operating: 3846900000.00
TORNTPHARM.NS income_statement (quarterly, 2026-03-31) — Interest Expense Non Operating: 2360000000.00
TORNTPHARM.NS income_statement (annual, 2026-03-31) — Interest Income: 384300000.00
TORNTPHARM.NS income_statement (annual, 2026-03-31) — Interest Income Non Operating: 384300000.00
TORNTPHARM.NS cash_flow (annual, 2026-03-31) — Interest Paid Cff: -4274600000.00
TORNTPHARM.NS cash_flow (annual, 2026-03-31) — Interest Received Cfi: 361400000.00
TORNTPHARM.NS balance_sheet (annual, 2026-03-31) — Inventory: 31381900000.00
TORNTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Inventory: 31381900000.00
TORNTPHARM.NS balance_sheet (annual, 2026-03-31) — Invested Capital: 231866700000.00
TORNTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Invested Capital: 231866700000.00
TORNTPHARM.NS cash_flow (annual, 2026-03-31) — Investing Cash Flow: -127124100000.00
TORNTPHARM.NS balance_sheet (annual, 2026-03-31) — Investment Properties: 131000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Investment Properties: 131000000.00
TORNTPHARM.NS balance_sheet (annual, 2026-03-31) — Investmentin Financial Assets: 994100000.00
TORNTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Investmentin Financial Assets: 994100000.00
TORNTPHARM.NS cash_flow (annual, 2026-03-31) — Issuance Of Debt: 125940500000.00
TORNTPHARM.NS balance_sheet (annual, 2026-03-31) — Land And Improvements: 12017200000.00
TORNTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Land And Improvements: 12017200000.00
TORNTPHARM.NS balance_sheet (annual, 2026-03-31) — Long Term Capital Lease Obligation: 1900700000.00
TORNTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Long Term Capital Lease Obligation: 1900700000.00
TORNTPHARM.NS balance_sheet (annual, 2026-03-31) — Long Term Debt: 116511700000.00
TORNTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Long Term Debt: 116511700000.00
TORNTPHARM.NS balance_sheet (annual, 2026-03-31) — Long Term Debt And Capital Lease Obligation: 118412400000.00
TORNTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Long Term Debt And Capital Lease Obligation: 118412400000.00
TORNTPHARM.NS cash_flow (annual, 2026-03-31) — Long Term Debt Issuance: 109900000000.00
TORNTPHARM.NS cash_flow (annual, 2026-03-31) — Long Term Debt Payments: -6721400000.00
TORNTPHARM.NS balance_sheet (annual, 2026-03-31) — Long Term Provisions: 7645500000.00
TORNTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Long Term Provisions: 7645500000.00
TORNTPHARM.NS balance_sheet (annual, 2026-03-31) — Machinery Furniture Equipment: 35042100000.00
TORNTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Machinery Furniture Equipment: 35042100000.00
TORNTPHARM.NS balance_sheet (annual, 2026-03-31) — Minority Interest: 91964000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Minority Interest: 91964000000.00
TORNTPHARM.NS income_statement (annual, 2026-03-31) — Minority Interests: 251900000.00
TORNTPHARM.NS income_statement (quarterly, 2026-03-31) — Minority Interests: 250000000.00
TORNTPHARM.NS cash_flow (annual, 2026-03-31) — Net Business Purchase And Sale: -123149500000.00
TORNTPHARM.NS balance_sheet (annual, 2026-03-31) — Net Debt: 136810400000.00
TORNTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Net Debt: 136810400000.00
TORNTPHARM.NS cash_flow (annual, 2026-03-31) — Net Foreign Currency Exchange Gain Loss: -1198900000.00
TORNTPHARM.NS income_statement (annual, 2026-03-31) — Net Income: 21633700000.00
TORNTPHARM.NS income_statement (quarterly, 2026-03-31) — Net Income: 3890000000.00
TORNTPHARM.NS income_statement (annual, 2026-03-31) — Net Income Common Stockholders: 21633700000.00
TORNTPHARM.NS income_statement (quarterly, 2026-03-31) — Net Income Common Stockholders: 3890000000.00
TORNTPHARM.NS income_statement (annual, 2026-03-31) — Net Income Continuous Operations: 21381800000.00
TORNTPHARM.NS income_statement (quarterly, 2026-03-31) — Net Income Continuous Operations: 3640000000.00
TORNTPHARM.NS income_statement (annual, 2026-03-31) — Net Income From Continuing And Discontinued Operation: 21633700000.00
TORNTPHARM.NS income_statement (quarterly, 2026-03-31) — Net Income From Continuing And Discontinued Operation: 3890000000.00
TORNTPHARM.NS income_statement (annual, 2026-03-31) — Net Income From Continuing Operation Net Minority Interest: 21633700000.00
TORNTPHARM.NS income_statement (quarterly, 2026-03-31) — Net Income From Continuing Operation Net Minority Interest: 3890000000.00
TORNTPHARM.NS cash_flow (annual, 2026-03-31) — Net Income From Continuing Operations: 28721900000.00
TORNTPHARM.NS income_statement (annual, 2026-03-31) — Net Income Including Noncontrolling Interests: 21381800000.00
TORNTPHARM.NS income_statement (quarterly, 2026-03-31) — Net Income Including Noncontrolling Interests: 3640000000.00
TORNTPHARM.NS income_statement (annual, 2026-03-31) — Net Interest Income: -3466400000.00
TORNTPHARM.NS income_statement (quarterly, 2026-03-31) — Net Interest Income: -2360000000.00
TORNTPHARM.NS cash_flow (annual, 2026-03-31) — Net Investment Purchase And Sale: 2028400000.00
TORNTPHARM.NS cash_flow (annual, 2026-03-31) — Net Issuance Payments Of Debt: 119219100000.00
TORNTPHARM.NS cash_flow (annual, 2026-03-31) — Net Long Term Debt Issuance: 103178600000.00
TORNTPHARM.NS income_statement (annual, 2026-03-31) — Net Non Operating Interest Income Expense: -3466400000.00
TORNTPHARM.NS income_statement (quarterly, 2026-03-31) — Net Non Operating Interest Income Expense: -2360000000.00
TORNTPHARM.NS balance_sheet (annual, 2026-03-31) — Net PPE: 53941200000.00
TORNTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Net PPE: 53941200000.00
TORNTPHARM.NS cash_flow (annual, 2026-03-31) — Net PPE Purchase And Sale: -6364400000.00
TORNTPHARM.NS cash_flow (annual, 2026-03-31) — Net Short Term Debt Issuance: 16040500000.00
TORNTPHARM.NS balance_sheet (annual, 2026-03-31) — Net Tangible Assets: -200647500000.00
TORNTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Net Tangible Assets: -200647500000.00
TORNTPHARM.NS balance_sheet (annual, 2026-03-31) — Non Current Deferred Revenue: 224000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Revenue: 224000000.00
TORNTPHARM.NS balance_sheet (annual, 2026-03-31) — Non Current Deferred Taxes Assets: 6982700000.00
TORNTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Taxes Assets: 6982700000.00
TORNTPHARM.NS balance_sheet (annual, 2026-03-31) — Non Current Deferred Taxes Liabilities: 56700400000.00
TORNTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Taxes Liabilities: 56700400000.00
TORNTPHARM.NS balance_sheet (annual, 2026-03-31) — Non Current Prepaid Assets: 231200000.00
TORNTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Non Current Prepaid Assets: 231200000.00
TORNTPHARM.NS income_statement (annual, 2026-03-31) — Normalized EBITDA: 44160700000.00
TORNTPHARM.NS income_statement (quarterly, 2026-03-31) — Normalized EBITDA: 13390000000.00
TORNTPHARM.NS income_statement (annual, 2026-03-31) — Normalized Income: 21933842080.00
TORNTPHARM.NS income_statement (quarterly, 2026-03-31) — Normalized Income: 4344139886.58
TORNTPHARM.NS cash_flow (annual, 2026-03-31) — Operating Cash Flow: 30227100000.00
TORNTPHARM.NS income_statement (annual, 2026-03-31) — Operating Income: 34397600000.00
TORNTPHARM.NS income_statement (quarterly, 2026-03-31) — Operating Income: 8480000000.00
TORNTPHARM.NS income_statement (annual, 2026-03-31) — Operating Revenue: 137529900000.00
TORNTPHARM.NS income_statement (quarterly, 2026-03-31) — Operating Revenue: 41280000000.00
TORNTPHARM.NS balance_sheet (annual, 2026-03-31) — Ordinary Shares Number: 338445440.00
TORNTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Ordinary Shares Number: 338445440.00
TORNTPHARM.NS balance_sheet (annual, 2026-03-31) — Other Current Assets: 6290000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Other Current Assets: 6290000000.00
TORNTPHARM.NS balance_sheet (annual, 2026-03-31) — Other Current Liabilities: 1000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Other Current Liabilities: 1000000.00
TORNTPHARM.NS balance_sheet (annual, 2026-03-31) — Other Equity Interest: 82192000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Other Equity Interest: 82192000000.00
TORNTPHARM.NS balance_sheet (annual, 2026-03-31) — Other Intangible Assets: 244635600000.00
TORNTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Other Intangible Assets: 244635600000.00
TORNTPHARM.NS balance_sheet (annual, 2026-03-31) — Other Inventories: 1141100000.00
TORNTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Other Inventories: 1141100000.00
TORNTPHARM.NS cash_flow (annual, 2026-03-31) — Other Non Cash Items: 3462200000.00
TORNTPHARM.NS balance_sheet (annual, 2026-03-31) — Other Non Current Assets: 310000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Other Non Current Assets: 310000000.00
TORNTPHARM.NS balance_sheet (annual, 2026-03-31) — Other Non Current Liabilities: 220000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Other Non Current Liabilities: 220000000.00
TORNTPHARM.NS income_statement (annual, 2026-03-31) — Other Non Operating Income Expenses: 28200000.00
TORNTPHARM.NS income_statement (quarterly, 2026-03-31) — Other Non Operating Income Expenses: -170000000.00
TORNTPHARM.NS income_statement (annual, 2026-03-31) — Other Operating Expenses: 6504700000.00
TORNTPHARM.NS income_statement (quarterly, 2026-03-31) — Other Operating Expenses: 10380000000.00
TORNTPHARM.NS balance_sheet (annual, 2026-03-31) — Other Payable: 6649700000.00
TORNTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Other Payable: 6649700000.00
TORNTPHARM.NS balance_sheet (annual, 2026-03-31) — Other Properties: 4043600000.00
TORNTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Other Properties: 4043600000.00
TORNTPHARM.NS balance_sheet (annual, 2026-03-31) — Other Receivables: 3099400000.00
TORNTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Other Receivables: 3099400000.00
TORNTPHARM.NS balance_sheet (annual, 2026-03-31) — Other Short Term Investments: 12380100000.00
TORNTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Other Short Term Investments: 12380100000.00
TORNTPHARM.NS income_statement (annual, 2026-03-31) — Other Special Charges: 710900000.00
TORNTPHARM.NS income_statement (quarterly, 2026-03-31) — Other Special Charges: -230000000.00
TORNTPHARM.NS income_statement (annual, 2026-03-31) — Otherunder Preferred Stock Dividend: 0.00
TORNTPHARM.NS income_statement (quarterly, 2026-03-31) — Otherunder Preferred Stock Dividend: 0.00
TORNTPHARM.NS balance_sheet (annual, 2026-03-31) — Payables: 31522500000.00
TORNTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Payables: 31522500000.00
TORNTPHARM.NS balance_sheet (annual, 2026-03-31) — Prepaid Assets: 1971200000.00
TORNTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Prepaid Assets: 1971200000.00
TORNTPHARM.NS income_statement (annual, 2026-03-31) — Pretax Income: 28721900000.00
TORNTPHARM.NS income_statement (quarterly, 2026-03-31) — Pretax Income: 5290000000.00
TORNTPHARM.NS balance_sheet (annual, 2026-03-31) — Properties: 0.00
TORNTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Properties: 0.00
TORNTPHARM.NS cash_flow (annual, 2026-03-31) — Provisionand Write Offof Assets: 55400000.00
TORNTPHARM.NS cash_flow (annual, 2026-03-31) — Purchase Of Business: -123149500000.00
TORNTPHARM.NS cash_flow (annual, 2026-03-31) — Purchase Of Investment: -127900000.00
TORNTPHARM.NS cash_flow (annual, 2026-03-31) — Purchase Of PPE: -6773900000.00
TORNTPHARM.NS balance_sheet (annual, 2026-03-31) — Raw Materials: 8432900000.00
TORNTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Raw Materials: 8432900000.00
TORNTPHARM.NS income_statement (annual, 2026-03-31) — Reconciled Cost Of Revenue: 35251100000.00
TORNTPHARM.NS income_statement (quarterly, 2026-03-31) — Reconciled Cost Of Revenue: 10150000000.00
TORNTPHARM.NS income_statement (annual, 2026-03-31) — Reconciled Depreciation: 11188700000.00
TORNTPHARM.NS income_statement (quarterly, 2026-03-31) — Reconciled Depreciation: 5080000000.00
TORNTPHARM.NS cash_flow (annual, 2026-03-31) — Repayment Of Debt: -6721400000.00
TORNTPHARM.NS income_statement (annual, 2026-03-31) — Research And Development: 449500000.00
TORNTPHARM.NS balance_sheet (annual, 2026-03-31) — Restricted Cash: 152600000.00
TORNTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Restricted Cash: 152600000.00
TORNTPHARM.NS income_statement (annual, 2026-03-31) — Restructuring And Mergern Acquisition: 890000000.00
TORNTPHARM.NS income_statement (quarterly, 2026-03-31) — Restructuring And Mergern Acquisition: 890000000.00
TORNTPHARM.NS cash_flow (annual, 2026-03-31) — Sale Of Investment: 2156300000.00
TORNTPHARM.NS cash_flow (annual, 2026-03-31) — Sale Of PPE: 409500000.00
TORNTPHARM.NS income_statement (annual, 2026-03-31) — Selling And Marketing Expense: 14909000000.00
TORNTPHARM.NS income_statement (annual, 2026-03-31) — Selling General And Administration: 23920600000.00
TORNTPHARM.NS balance_sheet (annual, 2026-03-31) — Share Issued: 338445440.00
TORNTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Share Issued: 338445440.00
TORNTPHARM.NS cash_flow (annual, 2026-03-31) — Short Term Debt Issuance: 16040500000.00
TORNTPHARM.NS income_statement (annual, 2026-03-31) — Special Income Charges: -712600000.00
TORNTPHARM.NS income_statement (quarterly, 2026-03-31) — Special Income Charges: -660000000.00
TORNTPHARM.NS balance_sheet (annual, 2026-03-31) — Stockholders Equity: 83884300000.00
TORNTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Stockholders Equity: 83884300000.00
TORNTPHARM.NS balance_sheet (annual, 2026-03-31) — Tangible Book Value: -200647500000.00
TORNTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Tangible Book Value: -200647500000.00
TORNTPHARM.NS income_statement (annual, 2026-03-31) — Tax Effect Of Unusual Items: -103057920.00
TORNTPHARM.NS income_statement (quarterly, 2026-03-31) — Tax Effect Of Unusual Items: -205860113.42
TORNTPHARM.NS income_statement (annual, 2026-03-31) — Tax Provision: 7340100000.00
TORNTPHARM.NS income_statement (quarterly, 2026-03-31) — Tax Provision: 1650000000.00
TORNTPHARM.NS income_statement (annual, 2026-03-31) — Tax Rate For Calcs: 0.26
TORNTPHARM.NS income_statement (quarterly, 2026-03-31) — Tax Rate For Calcs: 0.31
TORNTPHARM.NS balance_sheet (annual, 2026-03-31) — Taxes Receivable: 3438100000.00
TORNTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Taxes Receivable: 3438100000.00
TORNTPHARM.NS cash_flow (annual, 2026-03-31) — Taxes Refund Paid: -8089200000.00
TORNTPHARM.NS balance_sheet (annual, 2026-03-31) — Total Assets: 443119600000.00
TORNTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Total Assets: 443119600000.00
TORNTPHARM.NS balance_sheet (annual, 2026-03-31) — Total Capitalization: 200396000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Total Capitalization: 200396000000.00
TORNTPHARM.NS balance_sheet (annual, 2026-03-31) — Total Debt: 150255000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Total Debt: 150255000000.00
TORNTPHARM.NS balance_sheet (annual, 2026-03-31) — Total Equity Gross Minority Interest: 175848300000.00
TORNTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Total Equity Gross Minority Interest: 175848300000.00
TORNTPHARM.NS income_statement (annual, 2026-03-31) — Total Expenses: 103132300000.00
TORNTPHARM.NS income_statement (quarterly, 2026-03-31) — Total Expenses: 32800000000.00
TORNTPHARM.NS balance_sheet (annual, 2026-03-31) — Total Liabilities Net Minority Interest: 267271300000.00
TORNTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Total Liabilities Net Minority Interest: 267271300000.00
TORNTPHARM.NS balance_sheet (annual, 2026-03-31) — Total Non Current Assets: 349200700000.00
TORNTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Total Non Current Assets: 349200700000.00
TORNTPHARM.NS balance_sheet (annual, 2026-03-31) — Total Non Current Liabilities Net Minority Interest: 183838000000.00
TORNTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Total Non Current Liabilities Net Minority Interest: 183838000000.00
TORNTPHARM.NS income_statement (annual, 2026-03-31) — Total Other Finance Cost: 3800000.00
TORNTPHARM.NS balance_sheet (annual, 2026-03-31) — Total Tax Payable: 1208800000.00
TORNTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Total Tax Payable: 1208800000.00
TORNTPHARM.NS income_statement (annual, 2026-03-31) — Total Unusual Items: -403200000.00
TORNTPHARM.NS income_statement (quarterly, 2026-03-31) — Total Unusual Items: -660000000.00
TORNTPHARM.NS income_statement (annual, 2026-03-31) — Total Unusual Items Excluding Goodwill: -403200000.00
TORNTPHARM.NS income_statement (quarterly, 2026-03-31) — Total Unusual Items Excluding Goodwill: -660000000.00
TORNTPHARM.NS balance_sheet (annual, 2026-03-31) — Work In Process: 1882300000.00
TORNTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Work In Process: 1882300000.00
TORNTPHARM.NS balance_sheet (annual, 2026-03-31) — Working Capital: 10485600000.00
TORNTPHARM.NS balance_sheet (quarterly, 2026-03-31) — Working Capital: 10485600000.00
TORNTPOWER.NS balance_sheet (annual, 2022-03-31) — Accumulated Depreciation: -103765300000.00
TORNTPOWER.NS balance_sheet (annual, 2022-03-31) — Additional Paid In Capital: 1396300000.00
TORNTPOWER.NS balance_sheet (annual, 2022-03-31) — Allowance For Doubtful Accounts Receivable: -2177100000.00
TORNTPOWER.NS income_statement (annual, 2022-03-31) — Amortization: 106200000.00
TORNTPOWER.NS cash_flow (annual, 2022-03-31) — Amortization Cash Flow: 106200000.00
TORNTPOWER.NS balance_sheet (annual, 2022-03-31) — Buildings And Improvements: 18478600000.00
TORNTPOWER.NS balance_sheet (annual, 2022-03-31) — Cash Equivalents: 500000.00
TORNTPOWER.NS balance_sheet (annual, 2022-03-31) — Cash Financial: 2893600000.00
TORNTPOWER.NS cash_flow (annual, 2022-03-31) — Common Stock Dividend Paid: -7020400000.00
TORNTPOWER.NS balance_sheet (annual, 2022-03-31) — Current Deferred Taxes Liabilities: 1225400000.00
TORNTPOWER.NS balance_sheet (annual, 2022-03-31) — Dividends Payable: 105500000.00
TORNTPOWER.NS balance_sheet (annual, 2022-03-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 500000.00
TORNTPOWER.NS balance_sheet (annual, 2022-03-31) — Finished Goods: 263300000.00
TORNTPOWER.NS income_statement (annual, 2022-03-31) — General And Administrative Expense: 974900000.00
TORNTPOWER.NS balance_sheet (annual, 2022-03-31) — Gross Accounts Receivable: 18204100000.00
TORNTPOWER.NS balance_sheet (annual, 2022-03-31) — Held To Maturity Securities: 1168900000.00
TORNTPOWER.NS income_statement (annual, 2022-03-31) — Impairment Of Capital Assets: 13000000000.00
TORNTPOWER.NS income_statement (annual, 2022-03-31) — Interest Income: 666200000.00
TORNTPOWER.NS income_statement (annual, 2022-03-31) — Interest Income Non Operating: 666200000.00
TORNTPOWER.NS balance_sheet (annual, 2022-03-31) — Land And Improvements: 7243100000.00
TORNTPOWER.NS balance_sheet (annual, 2022-03-31) — Machinery Furniture Equipment: 247228300000.00
TORNTPOWER.NS balance_sheet (annual, 2022-03-31) — Non Current Deferred Revenue: 12063700000.00
TORNTPOWER.NS balance_sheet (annual, 2022-03-31) — Non Current Prepaid Assets: 10210000000.00
TORNTPOWER.NS balance_sheet (annual, 2022-03-31) — Other Inventories: 1718600000.00
TORNTPOWER.NS balance_sheet (annual, 2022-03-31) — Other Payable: 8829000000.00
TORNTPOWER.NS balance_sheet (annual, 2022-03-31) — Other Receivables: 20756000000.00
TORNTPOWER.NS income_statement (annual, 2022-03-31) — Other Special Charges: -65300000.00
TORNTPOWER.NS balance_sheet (annual, 2022-03-31) — Prepaid Assets: 1970100000.00
TORNTPOWER.NS balance_sheet (annual, 2022-03-31) — Properties: 0.00
TORNTPOWER.NS cash_flow (annual, 2022-03-31) — Purchase Of Business: -5152300000.00
TORNTPOWER.NS balance_sheet (annual, 2022-03-31) — Raw Materials: 3294200000.00
TORNTPOWER.NS income_statement (annual, 2022-03-31) — Rent And Landing Fees: 175500000.00
TORNTPOWER.NS income_statement (annual, 2022-03-31) — Rent Expense Supplemental: 175500000.00
TORNTPOWER.NS balance_sheet (annual, 2022-03-31) — Restricted Cash: 1310100000.00
TORNTPOWER.NS balance_sheet (annual, 2022-03-31) — Retained Earnings: 56456000000.00
TORNTPOWER.NS income_statement (annual, 2022-03-31) — Selling General And Administration: 974900000.00
TORNTPOWER.NS income_statement (annual, 2022-03-31) — Special Income Charges: -13403000000.00
TORNTPOWER.NS income_statement (annual, 2022-03-31) — Total Other Finance Cost: 142900000.00
TORNTPOWER.NS income_statement (annual, 2022-03-31) — Total Unusual Items: -12857300000.00
TORNTPOWER.NS income_statement (annual, 2022-03-31) — Total Unusual Items Excluding Goodwill: -12857300000.00
TORNTPOWER.NS balance_sheet (annual, 2022-03-31) — Work In Process: 99600000.00
TORNTPOWER.NS income_statement (annual, 2022-03-31) — Write Off: 468300000.00
TORNTPOWER.NS income_statement (annual, 2023-03-31) — +Operating Expense: 19675100000.00
TORNTPOWER.NS income_statement (annual, 2023-03-31) — +Total Revenue: 254028400000.00
TORNTPOWER.NS balance_sheet (annual, 2023-03-31) — Accounts Payable: 15226700000.00
TORNTPOWER.NS balance_sheet (annual, 2023-03-31) — Accounts Receivable: 22463300000.00
TORNTPOWER.NS balance_sheet (annual, 2023-03-31) — Accumulated Depreciation: -115820200000.00
TORNTPOWER.NS balance_sheet (annual, 2023-03-31) — Additional Paid In Capital: 612400000.00
TORNTPOWER.NS balance_sheet (annual, 2023-03-31) — Allowance For Doubtful Accounts Receivable: -2045000000.00
TORNTPOWER.NS income_statement (annual, 2023-03-31) — Amortization: 423400000.00
TORNTPOWER.NS cash_flow (annual, 2023-03-31) — Amortization Cash Flow: 423400000.00
TORNTPOWER.NS balance_sheet (annual, 2023-03-31) — Available For Sale Securities: 402900000.00
TORNTPOWER.NS income_statement (annual, 2023-03-31) — Basic Average Shares: 480616784.00
TORNTPOWER.NS income_statement (annual, 2023-03-31) — Basic EPS: 44.06